Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology
Author:
Kislikova Maria1ORCID, Lopez Maria Ana Batlle2, Salinas Francisco Javier Freire3, Blanco José Antonio Parra4, Molina Maria Pilar García-Berbel3, Fernandez Alejandro Aguilera1, Haces Vicente Celestino Piñera1, Unzueta Maria Teresa García5ORCID, Hernández Adalberto Benito1, Millan Juan Carlos Ruiz San1ORCID, Rodrigo Calabia Emilio1ORCID
Affiliation:
1. Immunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital—IDIVAL, 39009 Santander, Spain 2. Hematology Department, Marqués de Valdecilla University Hospital—IDIVAL, 39009 Santander, Spain 3. Pathology Department, Marqués de Valdecilla University Hospital—IDIVAL, 39009 Santander, Spain 4. Radiology Department, Marqués de Valdecilla University Hospital—IDIVAL, 39009 Santander, Spain 5. Clinical Laboratory Department, Marqués de Valdecilla University Hospital—IDIVAL, 39009 Santander, Spain
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent heart disease, troponin I, NT-Pro-BNP, and coronary calcification were measured. A massive sequencing was performed to detect CHIP. A total of 24.2% of the patients presented CHIP, including that which was only pathogenic. The most frequently affected gene was TET2 (21.1%). Using multivariate logistic regression analysis, the presence of CHIP was not related to coronary calcification (OR 0.387, 95% CI 0.142–1.058, p = 0.387), nor was it related to troponin I or NT-Pro-BNP. A total of nine patients developed major cardiovascular events. Patients with CHIP did not have a higher risk of major cardiovascular events, although patients with DNMT3A did have a higher risk (HR 6.637, 95% CI 1.443–30.533, p = 0.015), independent of other variables. We did not find that CHIP was associated with a greater risk of silent heart disease or cardiovascular events, although those affected by DNMT3a, analyzed independently, were associated with a greater number of cardiovascular events.
Funder
Marqués de Valdecilla University Hospital—IDIVAL research institute
Subject
Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics
Reference33 articles.
1. GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709–733. 2. The need for a cardionephrology subspecialty;Ortiz;Clin. Kidney J.,2021 3. Conference Participants. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review;Sarnak;J. Am. Coll. Cardiol.,2019 4. Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular disease;Zawada;Nephrol. Dial. Transplant.,2013 5. Hou, Y.C., Lu, C.L., Yuan, T.H., Liao, M.T., Chao, C.T., and Lu, K.C. (2020). The Epigenetic Landscape of Vascular Calcification: An Integrative Perspective. Int. J. Mol. Sci., 21.
|
|